ArticleAutism research and treatment2012
Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review.
Article in Autism research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome.Brain & development · 2017Trial
- A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.Journal of developmental and behavioral pediatrics : JDBP · 2016Trial
- Elevated serotonin receptor 2A signaling restores learning and memory in a Fragile X syndrome model.Scientific reports · 2026Article
- Acute administration of NLX-101, a Serotonin 1A receptor agonist, improves auditory temporal processing during development in a mouse model of Fragile X Syndrome.Journal of neurodevelopmental disorders · 2025Article
- Longitudinal Adaptive Behavioral Outcomes in Ogden Syndrome by Seizure Status and Therapeutic Intervention.medRxiv : the preprint server for health sciences · 2024Article
- Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome.SAGE open medicine · 2024Article
- An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment.Frontiers in neurology · 2020Review
- New Therapeutic Options for Fragile X Syndrome.Current treatment options in neurology · 2019Review
- Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature.Cannabis and cannabinoid research · 2019Review
- What's missing in autism spectrum disorder motor assessments?Journal of neurodevelopmental disorders · 2018Review
- Assessment of efficacy of prenatal genetic diagnosis for fragile X syndrome using nested PCR.Experimental and therapeutic medicine · 2018Article
- Fragile X syndrome and fragile X-associated disorders.F1000Research · 2017Review
- The neurobiology of the Prader-Willi phenotype of fragile X syndrome.Intractable & rare diseases research · 2016Review
- Review
- Molecular medicine of fragile X syndrome: based on known molecular mechanisms.World journal of pediatrics : WJP · 2016Review
- Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Current topics in behavioral neurosciences · 2016Review
- Identification of a male with fragile X syndrome through newborn screening.Intractable & rare diseases research · 2015Article
- Treatment of the psychiatric problems associated with fragile X syndrome.Current opinion in psychiatry · 2015Review
- Emerging pharmacologic treatment options for fragile X syndrome.The application of clinical genetics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Young children with fragile X syndrome (FXS) often experience anxiety, irritability, and hyperactivity related to sensory hyperarousal. However, there are no medication recommendations with documented efficacy for children under 5 years old of age with FXS. We examined data through a chart review for 45 children with FXS, 12-50 months old, using the Mullen Scales of Early Learning (MSEL) for baseline and longitudinal assessments. All children had clinical level of anxiety, language delays based on MSEL scores, and similar early learning composite (ELC) scores at their first visit to our clinic. Incidence of autism spectrum disorder (ASD) was similar in both groups. There were 11 children who were treated with sertraline, and these patients were retrospectively compared to 34 children who were not treated with sertraline by chart review. The baseline assessments were done at ages ranging from 18 to 44 months (mean 26.9, SD 7.99) and from 12 to 50 months (mean 29.94, SD 8.64) for treated and not treated groups, respectively. Mean rate of improvement in both expressive and receptive language development was significantly higher in the group who was treated with sertraline (P < 0.0001 and P = 0.0071, resp.). This data supports the need for a controlled trial of sertraline treatment in young children with FXS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.